Lido Advisors LLC Acquires 2,671 Shares of West Pharmaceutical Services, Inc. $WST

Lido Advisors LLC boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 187.7% during the first quarter, Holdings Channel.com reports. The firm owned 4,094 shares of the medical instruments supplier’s stock after acquiring an additional 2,671 shares during the quarter. Lido Advisors LLC’s holdings in West Pharmaceutical Services were worth $1,026,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Elyxium Wealth LLC purchased a new position in West Pharmaceutical Services during the fourth quarter valued at $25,000. Cornerstone Planning Group LLC raised its stake in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares during the last quarter. Bayban bought a new stake in West Pharmaceutical Services in the fourth quarter worth $27,000. Finally, Private Trust Co. NA boosted its holdings in West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $331.52 on Tuesday. The business’s fifty day simple moving average is $337.57 and its two-hundred day simple moving average is $287.85. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a market cap of $23.33 billion, a price-to-earnings ratio of 42.45, a P/E/G ratio of 2.56 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on WST shares. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday. Finally, Stephens reaffirmed an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $364.42.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.